GH Research to Present Clinical Trial Data at ECNP Meeting
Ticker: GHRS · Form: 6-K · Filed: Oct 10, 2025 · CIK: 1855129
Sentiment: neutral
Topics: clinical-trial-data, conference-presentation, pharmaceutical
TL;DR
GH Research presenting GH001 trial data at ECNP Oct 11-14, 2025.
AI Summary
GH Research PLC announced on October 10, 2025, that data from its GH001-TRD-201 clinical trial will be presented at the 38th European College of Neuropsychopharmacology (ECNP) annual meeting. The meeting is scheduled for October 11-14, 2025, in Amsterdam. Dr. Fabian Devlin will present a poster on October 13, 2025, and Prof. Bernhard T. Baune will also present a poster.
Why It Matters
The presentation of clinical trial data at a major scientific conference like ECNP is a key step in the drug development process, potentially impacting future regulatory approvals and market perception.
Risk Assessment
Risk Level: low — This filing is an informational announcement about a conference presentation and does not contain significant financial or operational changes.
Key Players & Entities
- GH Research PLC (company) — Registrant
- GH001-TRD-201 (clinical_trial) — Trial name
- 38th European College of Neuropsychopharmacology (ECNP) annual meeting (conference) — Event where data will be presented
- October 11-14, 2025 (date) — Date of ECNP meeting
- Amsterdam (location) — Location of ECNP meeting
- Dr. Fabian Devlin (person) — Presenter
- October 13, 2025 (date) — Date of Dr. Devlin's presentation
- Prof. Bernhard T. Baune (person) — Presenter
FAQ
What specific data from the GH001-TRD-201 trial will be presented?
The filing states that data from the GH001-TRD-201 clinical trial will be presented, but does not specify the exact nature or results of the data in this announcement.
When and where is the ECNP annual meeting taking place?
The 38th ECNP annual meeting is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands.
Who is presenting the data at the ECNP meeting?
Dr. Fabian Devlin and Prof. Bernhard T. Baune are scheduled to present posters at the ECNP meeting.
On what date will Dr. Fabian Devlin present his poster?
Dr. Fabian Devlin is scheduled to present his poster during Poster Session 3 on October 13, 2025.
Is this filing an annual report?
No, this is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of October 2025.
Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-10-10 07:00:20
Filing Documents
- ef20056725-6k.htm (6-K) — 10KB
- ef20056725_ex99-1.htm (EX-99.1) — 1KB
- ef20056725_ex99-2.htm (EX-99.2) — 1KB
- devlin.jpg (GRAPHIC) — 924KB
- safety.jpg (GRAPHIC) — 3395KB
- 0001140361-25-037846.txt ( ) — 5958KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38 th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands. A copy of the poster to be presented by Dr. Fabian Devlin during Poster Session 3 on October 13, 2025, is attached hereto as Exhibit 99.1. A copy of the poster to be presented by Prof. Bernhard T. Baune during Poster Session 4 on October 14, 2025, is attached hereto as Exhibit 99.2. 1 EXHIBIT INDEX 99.1 Poster to be presented by Dr. Fabian Devlin with Title: Psychoactive Effects of GH001 in Patients With Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomised Controlled Trial 99.2 Poster to be presented by Prof. Bernhard T. Baune with Title: Safety and Tolerability Results From a Phase 2b, Double-Blind Trial With an Open-Label Extension of GH001 in Treatment-Resistant Depression 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GH Research PLC Date: October 10, 2025 By: /s/ Julie Ryan Name: Julie Ryan Title: Vice President, Finance 3